Adamis Pharmaceuticals Corp
Company Snapshot: Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. In its specialty pharmaceutical pipeline, ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.
- Oct 8 2019 Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting
- Oct 1 2019 Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand
- Sep 26 2019 Adamis Pharmaceuticals Announces Presentation Pertaining to Its High Dose Naloxone Product Candidate at IHV Scientific Meeting
- Sep 3 2019 Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate